Sponsor
Amy C. Degnim
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04570956
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
Intervention
Placebo, Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
Condition
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia
Investigators
Amy Degnim, MD, Denice Gehling, RN, Lisa Seymour, B.S, Zachary Feldman, Seema Khan, M.D.